Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome

Specific mutations in MECP2 confer different severity. These results allow the design of therapies targeted toward the amelioration of expected problems. Furthermore, the distinct effects of MECP2 mutations on clinical severity must be considered in clinical intervention trials.